Trial Profile
Phase I study of epigenetic priming using decitabine with induction chemotherapy in patients with acute myelogenous leukemia (AML).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 09 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2007 New trial record.